MARKET

ORIC

ORIC

Oric Pharmaceuticals, Inc.
NASDAQ
11.39
+0.41
+3.73%
After Hours: 11.44 +0.05 +0.44% 19:24 12/04 EST
OPEN
10.91
PREV CLOSE
10.98
HIGH
11.54
LOW
10.72
VOLUME
1.27M
TURNOVER
--
52 WEEK HIGH
14.93
52 WEEK LOW
3.895
MARKET CAP
1.11B
P/E (TTM)
-6.5800
1D
5D
1M
3M
1Y
5Y
1D
Wedbush Keeps Their Buy Rating on Oric Pharmaceuticals (ORIC)
TipRanks · 18h ago
Oric Pharmaceuticals initiated as Early Stage Biotech at Goldman Sachs
TipRanks · 20h ago
Buy Rating for Oric Pharmaceuticals: Promising Developments and Enozertinib’s Potential in NSCLC Treatment
TipRanks · 1d ago
ORIC Pharma Announces Two Late-Breaking Oral Presentations Highlighting Data From Phase 1b Trial Of Enozertinib At ESMO Asia Congress 2025
Benzinga · 1d ago
Oric Pharmaceuticals Showcases Enozertinib Data at ESMO Asia Congress 2025
Reuters · 1d ago
ORIC® PHARMACEUTICALS ANNOUNCES ENOZERTINIB (ORIC-114) LATE-BREAKING ORAL PRESENTATIONS IN EGFR ATYPICAL AND EGFR EXON 20 NSCLC AT THE ESMO ASIA CONGRESS 2025
Reuters · 1d ago
Does ORIC (ORIC) Have the Scientific Depth to Turn Enozertinib Data Into Lasting Value?
Simply Wall St · 1d ago
Top 3 Health Care Stocks That May Rocket Higher In December
Benzinga · 1d ago
More
About ORIC
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on improving patients’ lives by Overcoming Resistance In Cancer. The Company is advancing a diverse pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. The Company's clinical-stage product candidates include ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-114, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers. In addition, the Company is also developing multiple discovery stage precision medicines targeting other hallmark cancer resistance mechanisms. Its out-licensing candidates include ORIC-533 and ORIC-613.

Webull offers ORIC Pharmaceuticals Inc stock information, including NASDAQ: ORIC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ORIC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ORIC stock methods without spending real money on the virtual paper trading platform.